Emeritus Professor Richard Christopherson

Professor
Member of the Order of Australia (AM)
School of Life and Environmental Sciences

G08 - Biochemistry and Microbiology Building
The University of Sydney

Telephone +61 2 9351 6031
Fax +61 2 9351 4726

Website Sydney Mass Spectrometry

Research interests

Research in our group focuses on the use of proteomics with mass spectrometry to develop new methods for classification of chronic lymphocytic leukemia (CLL) and for elucidation of the mechanisms of action of drugs effective in treating CLL, either singly or in combination. Ibrutinib and idelalisib are ‘small molecule’ inhibitors that have changed the ‘landscape’ for treatment of CLL. Ibrutininb inhibits Bruton’s tyrosine kinase, and idelalisib inhibits phosphoinositide 3-kinase δ. Our current research involves identification of proteins in samples of CLL whose levels of phosphorylation have changed (up or down) in cells treated with a kinase inhibitor. These changing patterns of phosphorylation (+ drug) should provide an explanation for how mitogenic signals pass from the B-cell receptor (BCR) on the plasma membrane of CLL cells to the nucleus to drive cellular proliferation, and how the kinase inhibitors block these signaling pathways. CLL has been attributed to tonic signaling by the BCR to stimulate proliferation that can be blocked by these kinase inhibitors. Identification of phosphorylated proteins is being done in collaboration with Prof Lee Graves (Department of Pharmacology, University of North Carolina, USA).

Fludarabine (2-FaraA) is a purine nucleoside analogue that is ‘front line’ treatment for CLL. In some cases of CLL, 2-FaraA may be effective as a single drug that may have up to 5 different mechanisms of action. One of these mechanisms is inhibition of DNA repair, resulting in strand breaks in DNA that activate several protein kinases (ATM, ATR and CHK1) that would change patterns of phosphorylation in CLL, and presumably also affect BCR signaling. Thus, the identification of proteins whose patterns of phosphorylation change has been extended to 2-FaraA, in collaboration with Prof Graves.

In a project with Dr Vivian Whittaker (University of Sydney, deceased), we have found more than 150 proteins in melanoma cells that are subject to AMPylation, the covalent attachment of AMP residues to tyrosine, threonine or serine. These AMPylated proteins may be produced by an enzyme called HYPE when cells are under stress, for example, in rapidly growing cancer cells where there are unfolded proteins in the endoplasmic reticulum (ER), called ER stress. AMPylation of proteins may produce the unfolded protein response that enables cancer cells to continue growing, rather than die.

In a separate project, we are developing engineered antibodies, called demibodies and conditional bispecific T cell engagers (cBITE), for use in the treatment of CLL. In collaboration with Prof Jacqui Matthews (SOLES, University of Sydney) and A/Prof Ashley Buckle (Protein Engineering and Design Lab, Monash University), we are constructing synthetic genes from cassettes that encode the multiple domains of these ‘engineered’ antibodies. The open reading frame encoding the whole protein is inserted into an expression plasmid, transfected into HEK293 cells, expressed and purified in milligram quantities. The efficacy of demibodies and cBITE will be tested in cultures of primary CLL cells from patients, using a novel culture system to maintain cell viability during the experiment in vitro.

Current research students

Project title Research student
AMPylation of proteins in melanoma cells and chronic lymphoid leukaemia cells maintained in the presence of adenosine and cAMP. Narjis FATIMA

Keywords

Melanoma and skin cancer; Haematological malignancy; Proteomics; Biochemistry; Colorectal cancers

Selected grants

2014

  • CLARIOstar Multifunctional Microplate Reader for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Huang M, Scolyer R, Fraser S, Sahni S, Speranza T, Owens T, Barrs V, Ju Y, Kovacevic Z, Lu Z, Camp A, Slobedman B, Morris B, Oliver B, Dos Remedios C, Kalinowski D, Fu D, Lai D, Lovicu F, Allbutt H, Triccas J, Burgess J, Kril J, Dixon K, Rendina L, Byrne M, King N, Groundwater P, Williamson P, Ho P, Dong Q, Bao B, Assinder S, McLennan S, Richardson D, Ammit A, Sharland A, Hardikar A, Hong A, Hambly B, Lee C, Murphy C, Goldsbury C, Johnstone D, Lane D, Hibbs D, Joshua D, Huq F, Halliday G, Sutherland G, Zreiqat H, Lok H, Lyons G, Jansson P, Black J, Zhu L, Sunde M, Day M, Naylor M, Buckland M, Murray M, Shafie N, Lay P, Poronnik P, Codd R, Mason R, Ryan R, Christopherson R, de Graaf S; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Application of biological nuclide labelling to probe the transduction of vibrational energy of enzymes to chemical potential for catalysis; Christopherson R; Australian Institute of Nuclear Science and Engineering (AINSE)/Awards.
  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho P, Williamson P, Murphy C; DVC Research/Equipment Grant.

2011

  • Melanoma Institute Australia Translational Research Program; Mann G, Thompson J, Kefford R, Menzies S, Scolyer R, Christopherson R, Rizos H, Spillane A, Zhang X, Hersey P; Cancer Institute NSW/Translational Program Grant.
  • Patterns of differentially abundant proteins on progressive chronic lymphocytic leukaemias; Christopherson R, Mulligan S; The Leukaemia Foundation of Australia Limited/Grants in Aid.

2010

  • A mass spectrometer for multiple reaction monitoring to validate cancer biomarkers; Christopherson R; Cancer Institute NSW/Equipment Grant.
  • Next-generation high-speed flow cytometric cell sorter; Fazekas de St Groth B, King N, Simpson S, Britton W, Campbell I, Vadas M, Grau G, Weninger W, Christopherson R, Gamble J, Rasko J, McCaughan G, Xia P, Beale P, Holst J, Haass N, Combes V, Saunders B, Byrne S, West N, Gorrell M, Bertolino P, Bowen D, Warner F, Seth D, Grimshaw M, Jolly C, Martiniello-Wilks R, Mrass P, Lyons G, Sword G; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2009

  • Core Resource Facility - application for 7-laser flow cytometer and high content bioimaging system to enhance capabilities and throughput for the NSW Advanced Cytometry Facility; King N, Vadas M, Campbell I, Grau G, Britton W, Fazekas de St Groth B, Richardson D, Halliday G, Christopherson R, Gamble J, Mason R, Rasko J, McCaughan G, Weninger W, Xia P, Gorrell M, Holst J, Pile A, Sword G, McArthur C, Dong Q, Haass N, Sharland A, Saunders B, Triccas J, Norris J, Bertolino P, Bowen D, Sze D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Script translational grant project; Christopherson R; New South Wales Health/Research Support.
  • 7-laser BD LSR-II and Cellomics Array Scan VTi to Enhance Capability and Throughput for the NSW Advanced Cytometry Facility; King N, Weninger W, Gunning P, Fazekas de St Groth B, Campbell I, Christopherson R, Black J, Mason R, Richardson D, Halliday G, Grau G, Gandevia S, Kachigian L, Geczy C, Jessup W, Vadas M, Britton W, Hunt N; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).

2008

  • Proteomic responses of B-lymphoproliferative disorders to fludarabine; Christopherson R, Mulligan S; The Leukaemia Foundation of Australia Limited/Grants in Aid.
  • Application of CD Antibody Microarray Tehcnology to Study the Effects of MAP kinase and HSP90 Inhibitors on Leukemia Cells; Graves M, Christopherson R, Graves M; University of Sydney/International Visiting Research Fellowship (IVRF).
  • CLLARC- Proteomic changes induced in Chronic Lymphocytic Leukaemia by Fludaranine; Christopherson R; Leukaemia Foundation of NSW/Research Grant Program.
  • Nanotherapeutics: nanoparticles with high specificity for the delivery and controlled release of drugs; Masters A, Maschmeyer T, Christopherson R; Australian Research Council (ARC)/Discovery Projects (DP).

2007

  • Proteomic screening for apoptotic markers in cancer; Baxter R, Leong S, Christopherson R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Funding the Proteomics Facility 2007-09; Christopherson R; University of Sydney/Internal Research Grant Allocations.
  • Use of Proteomic Analyses to improve the management of colorectal cancer - the SCRIPT for CRC Projec; Chan C, Kohonen-Corish M, Robertson G, Clarke S, Baker M, Beale P, Christopherson R, Bokey E, Horvath L, Lin B, Hong A, Solomon M, Chapuis P, McKay M, Mark M; Cancer Institute NSW/Translational Program Grant.

2006

  • Global phenotype profiling of chronic lymphocytic leukemia; Mulligan S, Christopherson R; CLL (Chronic Lymphocytic Leukemia) Global Research Foundation/Project Grant.
  • Sydney Melanoma Unit Translational Research Program; Mann G, Thompson J, Kefford R, Scolyer R, Menzies S, Hersey P, Christopherson R; Cancer Institute NSW/Translational Research Program Grant.
  • High resolution bioanalytical Fourier transform mass spectrometer combined with liquid chromatograph; Christopherson R, Baker M, Raftery M, Geczy C, James D, Harry E, Guilhaus M, Cavicchioli R, Stocker R, Wilkinson M, Dos Remedios C, Davey R; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).

2005

  • FACS Aria for the University of Sydney Flow Cytometry Facility; King N, Pollard J, Rasko J, Lovicu F, Bishop A, Bertolino P, Briscoe H, Gillies M, Madigan M, McAvoy J, Murphy C, Balcar V, Armour C, Hughes M, Reeve V, Christopherson R, Halliday G, Christie M, Pollock C, McCaughan G, Gorrell M, Dong Q, Abendroth A, Menzies S, Barnetson R, Byrne S, Hunt N, Hambly B, Cook D, Mason R, Day M, Black J; University of Sydney/Equipment Grant.
  • ProteomeX MS and personnel support for the new facuility; Baxter R, Christopherson R, Daly R, Guilhaus M, Kavallaris M, Clarke S, Molloy M, Baker M; Cancer Institute NSW/Research Support.

2004

  • Proteomic analysis of subcellular changes during apoptosis; Baxter R, Christopherson R; Australian Research Council (ARC)/Discovery Projects (DP).

2003

  • Recombinant malarial pyrimidine enzymes as drug targets; Christopherson R, Radajewski S; National Health and Medical Research Council (NHMRC)/Project Grants.
  • SELDI Protein Chip System; Baxter R, Christopherson R, King N; University of Sydney/Major Equipment Grant.

2002

  • Diagnosis of leukaemias by CD antigen expression; Chrisp J, Garret N, Christopherson R; Medsaic Pty Ltd/Research Support.
  • RC L3022 - Diagnosis of leukaemias by CD antigen expression & Protocol No X02-0056 & RC K0301- Inflammation and CD antigen expression: cardiopulmonary bypass v OPCAB surgery; Dos Remedios C, Christopherson R; Medsaic Pty Ltd/BLO Project.
  • Recombinant malarial pyrimidine enzymes as drug targets; Christopherson R; DVC Research/Bridging Support Grant.

2001

  • A recombinant protein facility at the University of Sydney; Christopherson R, Wake R, Basten A, Britton W; Wellcome Trust (UK)./Major Equipment Awards for Biomedical Research in Australia.

2000

  • Comparative determination of the three-dimensional structures of prokaryotic and mammalian dihydroorotases; Christopherson R; Australian Research Council (ARC)/Small Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Belov, L., Hallal, S., Matic, K., Zhou, J., Wissmueller, S., Ahmed, N., Tanjil, S., Mulligan, S., Best, O., Simpson, R., Christopherson, R. (2017). Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays. In David W. Greening, Richard J. Simpson (Eds.), Serum/Plasma Proteomics: Methods and Protocols, (pp. 263-301). New York: Humana Press. [More Information]
  • Zhou, J., Belov, L., Armstrong, N., Christopherson, R. (2013). Antibody Microarrays and Multiplexing. In Xiangdong Wang (Eds.), Bioinformatics of Human Proteomics, (pp. 331-359). Berlin: Springer. [More Information]
  • Christopherson, R. (2006). Nucleotide Biosynthesis. In Ganten, Detlev; Ruckpaul, Klaus (Eds.), Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine, (pp. 1333-1337). NY United States: Springer.

Journals

  • Sykes, E., McDonald, C., Ghazanfar, S., Mactier, S., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2018). A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics - Clinical Applications, 12(3), 1-12. [More Information]
  • Shen, Y., Best, O., Mulligan, S., Christopherson, R. (2018). Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. Leukemia & Lymphoma, 59(8), 1927-1937. [More Information]
  • Crassini, K., Pyke, T., Shen, Y., Stevenson, W., Christopherson, R., Mulligan, S., Best, O. (2018). Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. Leukemia & Lymphoma, 59(12), 2917-2928. [More Information]
  • Crassini, K., Shen, Y., Stevenson, W., Christopherson, R., Ward, C., Mulligan, S., Best, G. (2018). MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British Journal of Haematology, 182(3), 360-372. [More Information]
  • Crassini, K., Shen, Y., O'Dwyer, P., O'Neill, M., Christopherson, R., Mulligan, S., Best, G. (2018). The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. British Journal of Haematology, 182(5), 654-669. [More Information]
  • Mallawaaratchy, D., Hallal, S., Russell, B., Ly, L., Ebrahimkhani, S., Wei, H., Christopherson, R., Buckland, M., Kaufman (nee Alexander), K. (2017). Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease. Journal of Neuro-Oncology, 131(2), 233-244. [More Information]
  • Belov, L., Matic, K., Hallal, S., Best, G., Mulligan, S., Christopherson, R. (2016). Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. Journal of Extracellular Vesicles, 5(1), 1-12. [More Information]
  • Sykes, E., Mactier, S., Christopherson, R. (2016). Melanoma and the Unfolded Protein Response. Cancers, 8(3), 1-18. [More Information]
  • Huang, P., Mactier, S., Armacki, N., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 57(5), 1033-1043. [More Information]
  • Rahman, W., Tu, T., Budzinska, M., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Warner, F., Bowden, D., Thomspon, A., Bowen, D., Strasser, S., Sharland, A., Yang, J., McCaughan, G., Shackel, N., et al (2015). Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of differentiation Antibody Microarrays. Transplantation, 99(9), e120-e126. [More Information]
  • Mallawaaratchy, D., Buckland, M., McDonald, K., Li, C., Ly, L., Sykes, E., Christopherson, R., Kaufman (nee Alexander), K. (2015). Membrane proteome analysis of glioblastoma cell invasion. Journal of Neuropathology and Experimental Neurology, 74(5), 425-441. [More Information]
  • Mulligan, S., Alomari, M., Kaufman (nee Alexander), K., Mactier, S., Best, G., Christopherson, R. (2015). Rituximab induces major changes in the surface proteome of lipid rafts on human MEC1 chronic lymphocytic leukemia cells. Leukemia & Lymphoma, 56(Sup1), 9-9.
  • Kaufman (nee Alexander), K., Mactier, S., Christopherson, R. (2015). Surface Antigen Profiling of Surgical Melanoma Specimens. Methods in Molecular Biology, , 1-9. [More Information]
  • Zhou, J., Belov, L., Chapuis, P., Chan, C., Armstrong, N., Kaufman (nee Alexander), K., Solomon, M., Clarke, S., Christopherson, R. (2015). Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. Journal of Immunological Methods, 416, 59-68. [More Information]
  • Kaufman, K., Jenkins, Y., Alomari, M., Mirzaei, M., Best, O., Pascovici, D., Mactier, S., Mulligan, S., Haynes, P., Christopherson, R. (2015). The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 6(38), 40981-40997. [More Information]
  • Huang, P., Best, O., Almazi, J., Belov, L., Davies, Z., Majid, A., Dyer, M., Pascovici, D., Mulligan, S., Christopherson, R. (2014). Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 55(9), 2085-2092. [More Information]
  • Chik, J., Zhou, J., Moh, E., Christopherson, R., Clarke, S., Molloy, M., Packer, N. (2014). Comprehensive glycomics comparison between colon cancer cell cultures and tumours: Implications for biomarker studies. Journal of Proteomics, 108, 146-162. [More Information]
  • Kaufman (nee Alexander), K., Ly, L., McKay, M., Mallawaaratchy, D., Mactier, S., Crossett, B., Molloy, M., Buckland, M., McDonald, K., Christopherson, R. (2014). Comprehensive proteomic profiling of bevacizumab-resistant glioblastoma multiforme. Neuro-Oncology, 16(Suppl 2), ii98-ii98.
  • Christopherson, R., Mactier, S., Almazi, J., Kohnke, P., Best, O., Mulligan, S. (2014). Mechanisms of action of fludarabine nucleoside against human raji lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 33(4-6), 375-383. [More Information]
  • Mallawaaratchy, D., McDonald, K., Sykes, E., Buckland, M., Christopherson, R., Kaufman (nee Alexander), K. (2014). Novel proteins associated with invadopodia structures in glioblastoma. Neuro-Oncology, 16(Suppl 2), ii100-ii100. [More Information]
  • Alomari, M., Mactier, S., Kaufman (nee Alexander), K., Best, O., Mulligan, S., Christopherson, R. (2014). Profiling the lipid raft proteome from human MEC1 chronic lymphocytic Leukemia Cells. Journal of Proteomics & Bioinformatics, S7, 1-10. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Kaufman (nee Alexander), K., Mactier, S., Armstrong, N., Mallawaaratchy, D., Byrne, S., Haydu, L., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., Christopherson, R. (2014). Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 31, 407-421. [More Information]
  • Cooper, M., Cox, N., Zimmerman, E., Dewar, B., Duncan, J., Whittle, M., Nguyen, T., Jones, L., Roy, S., Smalley, D., Christopherson, R., et al (2013). Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia. PloS One, 8(6), 1-14. [More Information]
  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Yang, E., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2013). Identification of markers prognostic of survival in lymph node metastases from stage III melanoma patients. European Journal of Cancer, 49(Suppl 2), S874-S874.
  • Mallawaaratchy, D., Christopherson, R., Kaufman (nee Alexander), K. (2013). Membrane proteome analysis of invasive human glioblastoma multiforme. European Journal of Cancer, 49(Suppl 2), S132-S133.
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]
  • Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver International, 32(10), 1527-1534. [More Information]
  • Leong, S., McKay, M., Christopherson, R., Baxter, R. (2012). Biomarkers of Breast Cancer Apoptosis Induced by Chemotherapy and TRAIL. Journal of Proteome Research, 11(2), 1240-1250. [More Information]
  • Kohnke, P., Mactier, S., Almazi, J., Crossett, B., Christopherson, R. (2012). Fludarabine and Cladribine Induce Changes in Surface Proteins on Human B-Lymphoid Cell Lines Involved with Apoptosis, Cell Survival, and Antitumor Immunity. Journal of Proteome Research, 11(9), 4436-4448. [More Information]
  • Almazi, J., Mactier, S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Leong, S., Nunez, A., Lin, Z., Crossett, B., Christopherson, R., Baxter, R. (2012). iTRAQ-Based Proteomic Profiling of Breast Cancer Cell Response to Doxorubicin and TRAIL. Journal of Proteome Research, 11(7), 3561-3572. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia & Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia & Lymphoma, 53(7), 1367-1375. [More Information]
  • Mallawaaratchy, D., Mactier, S., Kaufman (nee Alexander), K., Blomfield, S., Christopherson, R. (2012). The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. Journal of Proteomics, 75(5), 1590-1599. [More Information]
  • Heath, E., Kaufman (nee Alexander), K., Christopherson, R. (2011). B-RAF: A Contributor to the Melanoma Phenotype. International Journal of Biochemistry and Cell Biology, 43(1), 29-32. [More Information]
  • Belov, L., Zhou, J., Christopherson, R. (2011). Cell Surface Markers in Colorectal Cancer Prognosis. International Journal of Molecular Sciences, 12(1), 78-113. [More Information]
  • Zhou, J., Belov, L., Solomon, M., Chan, C., Clarke, S., Christopherson, R. (2011). Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. Journal of Visualized Experiments, (55), 1-6. [More Information]
  • Mactier, S., Henrich, S., Che, Y., Kohnke, P., Christopherson, R. (2011). Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma. Journal of Proteome Research, 10(3), 1030-1042. [More Information]
  • Henrich, S., Mactier, S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]
  • Kaufman (nee Alexander), K., Belov, L., Huang, P., Mactier, S., Scolyer, R., Mann, G., Christopherson, R. (2010). An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 358(40210 (1-2)), 23-34. [More Information]
  • Cassano, C., Mactier, S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]
  • Yang, F., Tay, K., Dong, L., Thorne, R., Jiang, C., Yang, E., Tseng, H., Liu, H., Christopherson, R., Hersey, P., et al (2010). Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death and Differentiation, 17(8), 1354-1367. [More Information]
  • Zhou, J., Belov, L., Huang, P., Shin, J., Solomon, M., Chapuis, P., Bokey, E., Chan, C., Clarke, C., Clarke, S., Christopherson, R. (2010). Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. Journal of Immunological Methods, 355(40210 (1-2)), 40-51. [More Information]
  • Langley, D., Shojaei, M., Chan, C., Lok, H., Mackay, J., Traut, T., Guss, M., Christopherson, R. (2009). Corrections. Biochemistry, 48(11), 2569-2570. [More Information]
  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]
  • Barber, N., Belov, L., Christopherson, R. (2008). All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias. Leukemia Research: clinical and laboratory studies, 32, 315-322. [More Information]
  • Henrich, S., Mactier, S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]
  • Henrich, S., Christopherson, R. (2008). Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine. Leukemia, 22(3), 657-660. [More Information]
  • Ellmark, P., Hogerkorp, C., Ek, S., Belov, L., Berglund, M., Rosenquist, R., Christopherson, R., Borrebaeck, C. (2008). Phenotypic protein profiling of different B cell sub-populations using antibody CD-microarrays. Cancer Letters, 265(1), 98-106. [More Information]
  • Langley, D., Shojaei, M., Chan, C., Lok, H., Mackay, J., Traut, T., Guss, M., Christopherson, R. (2008). Structure and Inhibition of Orotidine 5'-Monophosphate Decarboxylase from Plasmodium falciparum. Biochemistry, 47(12), 3842-3854. [More Information]
  • Mactier, S., Crossett, B., Christopherson, R. (2007). Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. Biochimica et Biophysica Acta. Proteins and Proteomics, 1774 (9), 1173-1183. [More Information]
  • Henrich, S., Crossett, B., Christopherson, R. (2007). Differentially expressed nuclear proteins in human CCRF-CEM, HL-60, MECA and Raji cells correlate with cellular properties. Proteomics - Clinical Applications, 1(10), 1252-1265. [More Information]
  • Lee, M., Maher, M., Christopherson, R., Guss, M. (2007). Kinetic and Structural Analysis of Mutant Escherichia coli Dihydroorotases: A Flexible Loop Stabilizes the Transition State(,). Biochemistry, 46(37), 10538-10550. [More Information]
  • Leong, S., Christopherson, R., Baxter, R. (2007). Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cellular Physiology and Biochemistry, 20(5), 579-590. [More Information]
  • Lee, M., Chan, C., Graham, S., Christopherson, R., Guss, M., Maher, M. (2007). Structures of ligand-free and inhibitor complexes of dihydroorotase from Escherichia coli: Implications for loop movement in inhibitor design. Journal of Molecular Biology, 370(5), 812-825. [More Information]
  • Ellmark, P., Woolfson, A., Belov, L., Christopherson, R. (2007). The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human disease. Methods in Molecular Biology, 439(14). [More Information]
  • Henrich, S., Cordwell, S., Crossett, B., Baker, M., Christopherson, R. (2007). The nuclear proteome and DNA-binding fraction of human Raji lymphoma cells. Biochimica et Biophysica Acta. Proteins and Proteomics, 1774 (4), 413-432. [More Information]
  • Anderson, M., Cleland, W., Huang, D., Chan, C., Shojaei, M., Christopherson, R. (2006). 13C and 15N isotope effects for conversion of L-dihydroorotate to N-carbamyl-L-aspartate using dihydroorotase from hamster and Bacillus caldolyticus. Biochemistry, 45(23), 7132-7139. [More Information]
  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]
  • Ellmark, P., Belov, L., Huang, P., Lee, C., Solomon, M., Morgan, D., Christopherson, R. (2006). Multiplex detection of surface molecules on colorectal cancers. Proteomics, 6(6), 1791-1802. [More Information]
  • Woolfson, A., Ellmark, P., Chrisp, J., Scott, M., Christopherson, R. (2006). The application of CD antigen proteomics to pharmacogenomics. Pharmacogenomics, 7(5), 759-771. [More Information]
  • Huang, D., Kaplan, J., Menz, R., Katis, V., Wake, R., Zhao, F., Wolfenden, R., Christopherson, R. (2006). Thermodynamic Analysis of Catalysis by the Dihydroorotases from Hamster and Bacillus caldolyticus, As Compared with the Uncatalyzed Reaction. Biochemistry, 45(27), 8275-8283. [More Information]
  • Woolfson, A., Stebbing, J., Tom, B., Stoner, K., Gilks, W., Kreil, D., Mulligan, S., Belov, L., Chrisp, J., Errington, W., Christopherson, R., et al (2005). Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals. Blood, 106(3), 1003-1007. [More Information]
  • Lee, M., Chan, C., Guss, M., Christopherson, R., Maher, M. (2005). Dihydroorotase from Escherichia coli: loop movement and cooperativity between subunits. Journal of Molecular Biology, 348(3), 523-533. [More Information]
  • Georgiou, J., Skarratt, K., Fuller, S., Martin, C., Christopherson, R., Wiley, J., Sluyter, R. (2005). Human Epidermal and Monocyte-Derived Langerhans Cells Express Functional P2X7 Receptors. Journal of Investigative Dermatology, 125(3), 482-490. [More Information]
  • White, S., Belov, L., Barber, N., Hodgkin, P., Christopherson, R. (2005). Immunophenotypic changes induced on human HL60 leukaemia cells by 1alpha,25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate. Leukemia Research: clinical and laboratory studies, 29(10), 1141-1151. [More Information]
  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]
  • Kamal, M., Christopherson, R. (2004). Accumulation Of 5-Phosphoribosyl-1-Pyrophosphate In Human CCRF-CEM Leukaemia Cells Treated With Antifolates. International Journal of Biochemistry and Cell Biology, 36(3), 545-551. [More Information]
  • Christopherson, R., Cinquin, O., Shojaei, M., Kuehn, D., Menz, R. (2004). Cloning and expression of malarial pyrimidine enzymes. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 23(8&9), 1459-1465. [More Information]
  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731. [More Information]
  • Maher, M., Huang, D., Guss, M., Collyer, C., Christopherson, R. (2003). Crystallization of hamster dihydroorotase: involvement of a disulfide-linked tetrameric form. Acta Crystallographica. Section D: Biological Crystallography, 59(2), 381-384. [More Information]
  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]
  • Lal, S., Christopherson, R., Dos Remedios, C. (2002). Antibody arrays: an embryonic but rapidly growing technology. Drug Discovery Today, 7(18 Supplement), S143-S149. [More Information]
  • Christopherson, R., Lyons, S., Wilson, P. (2002). Inhibitors of de Novo nucleotide biosynthesis as drugs. Accounts Of Chemical Research, 35(11), 961-971. [More Information]
  • Menz, R., Cinquin, O., Christopherson, R. (2002). The identification, cloning and functional expression of the gene encoding orotidine 5'-monophosphate (OMP) decarboxylase from Plasmodium falciparum. Annals Of Tropical Medicine And Parasitology, 96(5), 469-476. [More Information]
  • Christopherson, R., Menz, R., Cinquin, O. (2001). A hybrid plasmid for expression of toxic malarial proteins in Escherichia coli. Molecular and Biochemical Parasitology, 117, 245-247.
  • Belov, L., de la Vega, O., Dos Remedios, C., Christopherson, R., Mulligan,, S. (2001). Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Research, 61(11), 4483-4489.

Conferences

  • Sluyter, R., Georgiou, J., Skarratt, K., Fuller, S., Martin, C., Christopherson, R., Wiley, J. (2005). Human epidermal and monocyte-derived langerhans cells express functional P2X7 receptors. 35th Annual Scientific Meeting of the Australasian Society for Immunology 2005, Denmark: Blackwell Munksgaard.

Patents

  • Christopherson, R., Matthews, J., Mackay, J. (2014). Therapeutic Agents. Patent No. 1962961, 5102772, 8623356.
  • Christopherson, R., Mackay, J., Matthews, J. (2014). Alternative Demibody Strategy For Cell Detection and Killing. Patent No. 2013201525.

Reference Works

  • Christopherson, R. (2008). CD antigens. In Schwab M (Eds.), Encyclopedia of Cancer. Springer.

2018

  • Sykes, E., McDonald, C., Ghazanfar, S., Mactier, S., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2018). A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics - Clinical Applications, 12(3), 1-12. [More Information]
  • Shen, Y., Best, O., Mulligan, S., Christopherson, R. (2018). Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. Leukemia & Lymphoma, 59(8), 1927-1937. [More Information]
  • Crassini, K., Pyke, T., Shen, Y., Stevenson, W., Christopherson, R., Mulligan, S., Best, O. (2018). Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. Leukemia & Lymphoma, 59(12), 2917-2928. [More Information]
  • Crassini, K., Shen, Y., Stevenson, W., Christopherson, R., Ward, C., Mulligan, S., Best, G. (2018). MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British Journal of Haematology, 182(3), 360-372. [More Information]
  • Crassini, K., Shen, Y., O'Dwyer, P., O'Neill, M., Christopherson, R., Mulligan, S., Best, G. (2018). The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. British Journal of Haematology, 182(5), 654-669. [More Information]

2017

  • Mallawaaratchy, D., Hallal, S., Russell, B., Ly, L., Ebrahimkhani, S., Wei, H., Christopherson, R., Buckland, M., Kaufman (nee Alexander), K. (2017). Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease. Journal of Neuro-Oncology, 131(2), 233-244. [More Information]
  • Belov, L., Hallal, S., Matic, K., Zhou, J., Wissmueller, S., Ahmed, N., Tanjil, S., Mulligan, S., Best, O., Simpson, R., Christopherson, R. (2017). Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays. In David W. Greening, Richard J. Simpson (Eds.), Serum/Plasma Proteomics: Methods and Protocols, (pp. 263-301). New York: Humana Press. [More Information]

2016

  • Belov, L., Matic, K., Hallal, S., Best, G., Mulligan, S., Christopherson, R. (2016). Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. Journal of Extracellular Vesicles, 5(1), 1-12. [More Information]
  • Sykes, E., Mactier, S., Christopherson, R. (2016). Melanoma and the Unfolded Protein Response. Cancers, 8(3), 1-18. [More Information]
  • Huang, P., Mactier, S., Armacki, N., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 57(5), 1033-1043. [More Information]

2015

  • Rahman, W., Tu, T., Budzinska, M., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Warner, F., Bowden, D., Thomspon, A., Bowen, D., Strasser, S., Sharland, A., Yang, J., McCaughan, G., Shackel, N., et al (2015). Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of differentiation Antibody Microarrays. Transplantation, 99(9), e120-e126. [More Information]
  • Mallawaaratchy, D., Buckland, M., McDonald, K., Li, C., Ly, L., Sykes, E., Christopherson, R., Kaufman (nee Alexander), K. (2015). Membrane proteome analysis of glioblastoma cell invasion. Journal of Neuropathology and Experimental Neurology, 74(5), 425-441. [More Information]
  • Mulligan, S., Alomari, M., Kaufman (nee Alexander), K., Mactier, S., Best, G., Christopherson, R. (2015). Rituximab induces major changes in the surface proteome of lipid rafts on human MEC1 chronic lymphocytic leukemia cells. Leukemia & Lymphoma, 56(Sup1), 9-9.
  • Kaufman (nee Alexander), K., Mactier, S., Christopherson, R. (2015). Surface Antigen Profiling of Surgical Melanoma Specimens. Methods in Molecular Biology, , 1-9. [More Information]
  • Zhou, J., Belov, L., Chapuis, P., Chan, C., Armstrong, N., Kaufman (nee Alexander), K., Solomon, M., Clarke, S., Christopherson, R. (2015). Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. Journal of Immunological Methods, 416, 59-68. [More Information]
  • Kaufman, K., Jenkins, Y., Alomari, M., Mirzaei, M., Best, O., Pascovici, D., Mactier, S., Mulligan, S., Haynes, P., Christopherson, R. (2015). The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 6(38), 40981-40997. [More Information]

2014

  • Huang, P., Best, O., Almazi, J., Belov, L., Davies, Z., Majid, A., Dyer, M., Pascovici, D., Mulligan, S., Christopherson, R. (2014). Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 55(9), 2085-2092. [More Information]
  • Chik, J., Zhou, J., Moh, E., Christopherson, R., Clarke, S., Molloy, M., Packer, N. (2014). Comprehensive glycomics comparison between colon cancer cell cultures and tumours: Implications for biomarker studies. Journal of Proteomics, 108, 146-162. [More Information]
  • Kaufman (nee Alexander), K., Ly, L., McKay, M., Mallawaaratchy, D., Mactier, S., Crossett, B., Molloy, M., Buckland, M., McDonald, K., Christopherson, R. (2014). Comprehensive proteomic profiling of bevacizumab-resistant glioblastoma multiforme. Neuro-Oncology, 16(Suppl 2), ii98-ii98.
  • Christopherson, R., Matthews, J., Mackay, J. (2014). Therapeutic Agents. Patent No. 1962961, 5102772, 8623356.
  • Christopherson, R., Mactier, S., Almazi, J., Kohnke, P., Best, O., Mulligan, S. (2014). Mechanisms of action of fludarabine nucleoside against human raji lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 33(4-6), 375-383. [More Information]
  • Mallawaaratchy, D., McDonald, K., Sykes, E., Buckland, M., Christopherson, R., Kaufman (nee Alexander), K. (2014). Novel proteins associated with invadopodia structures in glioblastoma. Neuro-Oncology, 16(Suppl 2), ii100-ii100. [More Information]
  • Alomari, M., Mactier, S., Kaufman (nee Alexander), K., Best, O., Mulligan, S., Christopherson, R. (2014). Profiling the lipid raft proteome from human MEC1 chronic lymphocytic Leukemia Cells. Journal of Proteomics & Bioinformatics, S7, 1-10. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Kaufman (nee Alexander), K., Mactier, S., Armstrong, N., Mallawaaratchy, D., Byrne, S., Haydu, L., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., Christopherson, R. (2014). Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 31, 407-421. [More Information]
  • Christopherson, R., Mackay, J., Matthews, J. (2014). Alternative Demibody Strategy For Cell Detection and Killing. Patent No. 2013201525.

2013

  • Zhou, J., Belov, L., Armstrong, N., Christopherson, R. (2013). Antibody Microarrays and Multiplexing. In Xiangdong Wang (Eds.), Bioinformatics of Human Proteomics, (pp. 331-359). Berlin: Springer. [More Information]
  • Cooper, M., Cox, N., Zimmerman, E., Dewar, B., Duncan, J., Whittle, M., Nguyen, T., Jones, L., Roy, S., Smalley, D., Christopherson, R., et al (2013). Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia. PloS One, 8(6), 1-14. [More Information]
  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Yang, E., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2013). Identification of markers prognostic of survival in lymph node metastases from stage III melanoma patients. European Journal of Cancer, 49(Suppl 2), S874-S874.
  • Mallawaaratchy, D., Christopherson, R., Kaufman (nee Alexander), K. (2013). Membrane proteome analysis of invasive human glioblastoma multiforme. European Journal of Cancer, 49(Suppl 2), S132-S133.
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]

2012

  • Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver International, 32(10), 1527-1534. [More Information]
  • Leong, S., McKay, M., Christopherson, R., Baxter, R. (2012). Biomarkers of Breast Cancer Apoptosis Induced by Chemotherapy and TRAIL. Journal of Proteome Research, 11(2), 1240-1250. [More Information]
  • Kohnke, P., Mactier, S., Almazi, J., Crossett, B., Christopherson, R. (2012). Fludarabine and Cladribine Induce Changes in Surface Proteins on Human B-Lymphoid Cell Lines Involved with Apoptosis, Cell Survival, and Antitumor Immunity. Journal of Proteome Research, 11(9), 4436-4448. [More Information]
  • Almazi, J., Mactier, S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Leong, S., Nunez, A., Lin, Z., Crossett, B., Christopherson, R., Baxter, R. (2012). iTRAQ-Based Proteomic Profiling of Breast Cancer Cell Response to Doxorubicin and TRAIL. Journal of Proteome Research, 11(7), 3561-3572. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia & Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia & Lymphoma, 53(7), 1367-1375. [More Information]
  • Mallawaaratchy, D., Mactier, S., Kaufman (nee Alexander), K., Blomfield, S., Christopherson, R. (2012). The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. Journal of Proteomics, 75(5), 1590-1599. [More Information]

2011

  • Heath, E., Kaufman (nee Alexander), K., Christopherson, R. (2011). B-RAF: A Contributor to the Melanoma Phenotype. International Journal of Biochemistry and Cell Biology, 43(1), 29-32. [More Information]
  • Belov, L., Zhou, J., Christopherson, R. (2011). Cell Surface Markers in Colorectal Cancer Prognosis. International Journal of Molecular Sciences, 12(1), 78-113. [More Information]
  • Zhou, J., Belov, L., Solomon, M., Chan, C., Clarke, S., Christopherson, R. (2011). Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. Journal of Visualized Experiments, (55), 1-6. [More Information]
  • Mactier, S., Henrich, S., Che, Y., Kohnke, P., Christopherson, R. (2011). Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma. Journal of Proteome Research, 10(3), 1030-1042. [More Information]
  • Henrich, S., Mactier, S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]

2010

  • Kaufman (nee Alexander), K., Belov, L., Huang, P., Mactier, S., Scolyer, R., Mann, G., Christopherson, R. (2010). An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 358(40210 (1-2)), 23-34. [More Information]
  • Cassano, C., Mactier, S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]
  • Yang, F., Tay, K., Dong, L., Thorne, R., Jiang, C., Yang, E., Tseng, H., Liu, H., Christopherson, R., Hersey, P., et al (2010). Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death and Differentiation, 17(8), 1354-1367. [More Information]
  • Zhou, J., Belov, L., Huang, P., Shin, J., Solomon, M., Chapuis, P., Bokey, E., Chan, C., Clarke, C., Clarke, S., Christopherson, R. (2010). Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. Journal of Immunological Methods, 355(40210 (1-2)), 40-51. [More Information]

2009

  • Langley, D., Shojaei, M., Chan, C., Lok, H., Mackay, J., Traut, T., Guss, M., Christopherson, R. (2009). Corrections. Biochemistry, 48(11), 2569-2570. [More Information]
  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]

2008

  • Barber, N., Belov, L., Christopherson, R. (2008). All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias. Leukemia Research: clinical and laboratory studies, 32, 315-322. [More Information]
  • Christopherson, R. (2008). CD antigens. In Schwab M (Eds.), Encyclopedia of Cancer. Springer.
  • Henrich, S., Mactier, S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]
  • Henrich, S., Christopherson, R. (2008). Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine. Leukemia, 22(3), 657-660. [More Information]
  • Ellmark, P., Hogerkorp, C., Ek, S., Belov, L., Berglund, M., Rosenquist, R., Christopherson, R., Borrebaeck, C. (2008). Phenotypic protein profiling of different B cell sub-populations using antibody CD-microarrays. Cancer Letters, 265(1), 98-106. [More Information]
  • Langley, D., Shojaei, M., Chan, C., Lok, H., Mackay, J., Traut, T., Guss, M., Christopherson, R. (2008). Structure and Inhibition of Orotidine 5'-Monophosphate Decarboxylase from Plasmodium falciparum. Biochemistry, 47(12), 3842-3854. [More Information]

2007

  • Mactier, S., Crossett, B., Christopherson, R. (2007). Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. Biochimica et Biophysica Acta. Proteins and Proteomics, 1774 (9), 1173-1183. [More Information]
  • Henrich, S., Crossett, B., Christopherson, R. (2007). Differentially expressed nuclear proteins in human CCRF-CEM, HL-60, MECA and Raji cells correlate with cellular properties. Proteomics - Clinical Applications, 1(10), 1252-1265. [More Information]
  • Lee, M., Maher, M., Christopherson, R., Guss, M. (2007). Kinetic and Structural Analysis of Mutant Escherichia coli Dihydroorotases: A Flexible Loop Stabilizes the Transition State(,). Biochemistry, 46(37), 10538-10550. [More Information]
  • Leong, S., Christopherson, R., Baxter, R. (2007). Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cellular Physiology and Biochemistry, 20(5), 579-590. [More Information]
  • Lee, M., Chan, C., Graham, S., Christopherson, R., Guss, M., Maher, M. (2007). Structures of ligand-free and inhibitor complexes of dihydroorotase from Escherichia coli: Implications for loop movement in inhibitor design. Journal of Molecular Biology, 370(5), 812-825. [More Information]
  • Ellmark, P., Woolfson, A., Belov, L., Christopherson, R. (2007). The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human disease. Methods in Molecular Biology, 439(14). [More Information]
  • Henrich, S., Cordwell, S., Crossett, B., Baker, M., Christopherson, R. (2007). The nuclear proteome and DNA-binding fraction of human Raji lymphoma cells. Biochimica et Biophysica Acta. Proteins and Proteomics, 1774 (4), 413-432. [More Information]

2006

  • Anderson, M., Cleland, W., Huang, D., Chan, C., Shojaei, M., Christopherson, R. (2006). 13C and 15N isotope effects for conversion of L-dihydroorotate to N-carbamyl-L-aspartate using dihydroorotase from hamster and Bacillus caldolyticus. Biochemistry, 45(23), 7132-7139. [More Information]
  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]
  • Ellmark, P., Belov, L., Huang, P., Lee, C., Solomon, M., Morgan, D., Christopherson, R. (2006). Multiplex detection of surface molecules on colorectal cancers. Proteomics, 6(6), 1791-1802. [More Information]
  • Christopherson, R. (2006). Nucleotide Biosynthesis. In Ganten, Detlev; Ruckpaul, Klaus (Eds.), Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine, (pp. 1333-1337). NY United States: Springer.
  • Woolfson, A., Ellmark, P., Chrisp, J., Scott, M., Christopherson, R. (2006). The application of CD antigen proteomics to pharmacogenomics. Pharmacogenomics, 7(5), 759-771. [More Information]
  • Huang, D., Kaplan, J., Menz, R., Katis, V., Wake, R., Zhao, F., Wolfenden, R., Christopherson, R. (2006). Thermodynamic Analysis of Catalysis by the Dihydroorotases from Hamster and Bacillus caldolyticus, As Compared with the Uncatalyzed Reaction. Biochemistry, 45(27), 8275-8283. [More Information]

2005

  • Woolfson, A., Stebbing, J., Tom, B., Stoner, K., Gilks, W., Kreil, D., Mulligan, S., Belov, L., Chrisp, J., Errington, W., Christopherson, R., et al (2005). Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals. Blood, 106(3), 1003-1007. [More Information]
  • Lee, M., Chan, C., Guss, M., Christopherson, R., Maher, M. (2005). Dihydroorotase from Escherichia coli: loop movement and cooperativity between subunits. Journal of Molecular Biology, 348(3), 523-533. [More Information]
  • Georgiou, J., Skarratt, K., Fuller, S., Martin, C., Christopherson, R., Wiley, J., Sluyter, R. (2005). Human Epidermal and Monocyte-Derived Langerhans Cells Express Functional P2X7 Receptors. Journal of Investigative Dermatology, 125(3), 482-490. [More Information]
  • Sluyter, R., Georgiou, J., Skarratt, K., Fuller, S., Martin, C., Christopherson, R., Wiley, J. (2005). Human epidermal and monocyte-derived langerhans cells express functional P2X7 receptors. 35th Annual Scientific Meeting of the Australasian Society for Immunology 2005, Denmark: Blackwell Munksgaard.
  • White, S., Belov, L., Barber, N., Hodgkin, P., Christopherson, R. (2005). Immunophenotypic changes induced on human HL60 leukaemia cells by 1alpha,25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate. Leukemia Research: clinical and laboratory studies, 29(10), 1141-1151. [More Information]
  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]

2004

  • Kamal, M., Christopherson, R. (2004). Accumulation Of 5-Phosphoribosyl-1-Pyrophosphate In Human CCRF-CEM Leukaemia Cells Treated With Antifolates. International Journal of Biochemistry and Cell Biology, 36(3), 545-551. [More Information]
  • Christopherson, R., Cinquin, O., Shojaei, M., Kuehn, D., Menz, R. (2004). Cloning and expression of malarial pyrimidine enzymes. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 23(8&9), 1459-1465. [More Information]
  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731. [More Information]

2003

  • Maher, M., Huang, D., Guss, M., Collyer, C., Christopherson, R. (2003). Crystallization of hamster dihydroorotase: involvement of a disulfide-linked tetrameric form. Acta Crystallographica. Section D: Biological Crystallography, 59(2), 381-384. [More Information]
  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]

2002

  • Lal, S., Christopherson, R., Dos Remedios, C. (2002). Antibody arrays: an embryonic but rapidly growing technology. Drug Discovery Today, 7(18 Supplement), S143-S149. [More Information]
  • Christopherson, R., Lyons, S., Wilson, P. (2002). Inhibitors of de Novo nucleotide biosynthesis as drugs. Accounts Of Chemical Research, 35(11), 961-971. [More Information]
  • Menz, R., Cinquin, O., Christopherson, R. (2002). The identification, cloning and functional expression of the gene encoding orotidine 5'-monophosphate (OMP) decarboxylase from Plasmodium falciparum. Annals Of Tropical Medicine And Parasitology, 96(5), 469-476. [More Information]

2001

  • Christopherson, R., Menz, R., Cinquin, O. (2001). A hybrid plasmid for expression of toxic malarial proteins in Escherichia coli. Molecular and Biochemical Parasitology, 117, 245-247.
  • Belov, L., de la Vega, O., Dos Remedios, C., Christopherson, R., Mulligan,, S. (2001). Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Research, 61(11), 4483-4489.

To update your profile click here. For support on your academic profile contact .